A. Sinclair Dunlop is Director at Apellis Pharmaceuticals, Inc. (APLS). They have made 16 open-market trades across 1 company since 2019, most recently 2026-01-01.
CIK 0001721108
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 16 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 161,567 | $6.6M |
Shares reported on the most recent Form 4, priced at the 2026-01-05 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL · 10b5-1 | 2025-10-10 | 2025-10-15 | $23.72 | $1.5M | +18.1% | -19.4% | -15.4% |
| APLS | SELL · 10b5-1 | 2025-09-30 | 2025-10-02 | $22.58 | $1.4M | +0.3% | -10.4% | +8.8% |
| APLS | SELL · 10b5-1 | 2025-09-19 | 2025-09-19 | $22.95 | $1.4M | +0.0% | +17.2% | +6.0% |
| APLS | SELL | 2024-09-16 | 2024-09-17 | $36.23 | $2.7M | -17.7% | -22.0% | -6.0% |
| APLS | SELL | 2024-06-21 | 2024-06-21 | $39.24 | $2.9M | -7.1% | -2.8% | -3.6% |
| APLS | SELL | 2024-03-19 | 2024-03-20 | $57.18 | $2.1M | -0.5% | -15.1% | -28.4% |
| APLS | SELL | 2023-12-01 | 2023-12-05 | $61.14 | $1.5M | -18.7% | -6.3% | -0.3% |
| APLS | SELL | 2023-11-17 | 2023-11-21 | $49.99 | $889K | +29.0% | +10.0% | +37.1% |
| APLS | SELL | 2023-10-17 | 2023-11-21 | $49.00 | $1.2M | +29.0% | +10.0% | +37.1% |
| APLS | SELL · 10b5-1 | 2023-04-03 | 2023-04-05 | $74.05 | $37K | +6.2% | +20.4% | +14.1% |
| APLS | SELL · 10b5-1 | 2023-03-01 | 2023-03-02 | $65.33 | $33K | +2.1% | +20.1% | +34.5% |
| APLS | SELL · 10b5-1 | 2023-02-01 | 2023-02-02 | $52.61 | $26K | -7.4% | +15.1% | +52.2% |
| APLS | SELL · 10b5-1 | 2023-01-03 | 2023-01-05 | $50.70 | $25K | +7.3% | +15.2% | +61.4% |
| APLS | SELL · 10b5-1 | 2022-12-01 | 2022-12-02 | $49.93 | $25K | +4.6% | -0.2% | +27.8% |
| APLS | SELL · 10b5-1 | 2022-11-01 | 2022-11-03 | $60.83 | $30K | -6.8% | -1.2% | +10.1% |
| APLS | SELL | 2022-09-08 | 2022-09-08 | $65.00 | $975K | -7.9% | -16.1% | -31.1% |
| APLS | SELL | 2022-08-11 | 2022-08-12 | $65.63 | $3.9M | -9.1% | +0.1% | -32.9% |
| APLS | SELL | 2022-06-27 | 2022-06-29 | $46.79 | $125K | +8.8% | +27.5% | +39.9% |
| APLS | SELL | 2022-06-23 | 2022-06-24 | $45.00 | $675K | +6.2% | +18.0% | +32.7% |
| APLS | SELL | 2021-05-18 | 2021-05-20 | $52.57 | $16.1M | +13.5% | +24.5% | +19.2% |
| APLS | SELL | 2020-12-14 | 2020-12-15 | $54.66 | $2.7M | +6.8% | +2.0% | -10.4% |
| APLS | SELL | 2020-12-04 | 2020-12-07 | $50.50 | $2.0M | +5.1% | +10.7% | -8.1% |
| APLS | SELL | 2019-12-19 | 2019-12-20 | $28.99 | $1.6M | +5.1% | +43.5% | -23.7% |
| APLS | SELL | 2019-12-18 | 2019-12-20 | $28.55 | $739K | +5.1% | +43.5% | -23.7% |
| APLS | SELL | 2019-12-18 | 2019-12-20 | $29.12 | $4.0M | +5.1% | +43.5% | -23.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.